METHODS: A comprehensive search was conducted on PubMed, Cochrane (CENTRAL), ScienceDirect, and Embase for randomized controlled trials (RCTs) comparing combination therapy with an MRA or ASI and an SGLT2 inhibitor with SGLT2 inhibitor monotherapy in patients with CKD. This evidence concerns the gene SLC5A2 and chronic kidney disease.